Atara Biotherapeutics Says Carol Gallagher To Replace Ron Renaud As Chair Of The Board Of Directors

RTTNews | 876天前
Atara Biotherapeutics Says Carol Gallagher To Replace Ron Renaud As Chair Of The Board Of Directors

(RTTNews) - Atara Biotherapeutics, Inc. (ATRA) announced Monday that Carol Gallagher will assume the role of Chair of the Board of Directors, replacing Ron Renaud, who is stepping down to focus on his new position as Managing Director at Bain Capital Life Sciences.

Gallagher is a venture partner in the life sciences practice of New Enterprise Associates and an experienced public company director. She has served as a Director at Atara since 2013 and as a member of both the Compensation and Nominating and Corporate Governance Committees.

Gallagher was formerly the President and CEO of Calistoga Pharmaceuticals and has held commercial and drug development roles within Eli Lilly, Amgen, Agouron, Pfizer and Biogen Idec.

Atara also announced that after four years of service, Roy Baynes, has decided to step down from Atara's Board of Directors to pursue other external opportunities following his retirement from Merck.

read more
Atara's Ebvallo Receives European Commission Approval For Adults And Children With EBV+ PTLD

Atara's Ebvallo Receives European Commission Approval For Adults And Children With EBV+ PTLD

Atara Biotherapeutics, Inc. (ATRA) and French healthcare company Pierre Fabre announced Monday that the European Commission (EC) has granted marketing authorization for Ebvallo (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
RTTNews | 876天前
U.S. Small Business Optimism Erodes Further On High Uncertainty - NFIB

U.S. Small Business Optimism Erodes Further On High Uncertainty - NFIB

Confidence among the U.S. small businesses fell for the fourth straight month in April as firms turned more cautious in the face of significant uncertainty caused by the Trump administration's trade tariff policy, survey data from the National Federation of Independent Business showed on Tuesday.
RTTNews | 2小時6分鐘前
U.S. Dollar Weakens As Inflation Slows

U.S. Dollar Weakens As Inflation Slows

The U.S. dollar came under pressure on Tuesday, as inflation slowed more than expected in April, raising hopes of further easing by the Federal Reserve.
RTTNews | 3小時27分鐘前
TSX Extending Recent Gains, Up Nearly 0.5%

TSX Extending Recent Gains, Up Nearly 0.5%

The Canadian market is up in positive territory on Tuesday, extending recent gains, amid easing tensions about tariffs following the two largest economies of the world, China and the U.S. agreeing on a trade deal, and data showing a less than expected increase in U.S. consumer price inflation in the month of April.
RTTNews | 4小時12分鐘前
Swiss Market Ends On Weak Note

Swiss Market Ends On Weak Note

After a flat start and a subsequent modest upmove, the Switzerland market pared gains and drifted down into negative territory about an hour past noon and finally settled on a weak note. A lack of fresh triggers, and uncertainty about U.S.-European Union trade deal rendered the mood cautious.
RTTNews | 4小時29分鐘前
European Stocks Close Slightly Higher After Cautious Session

European Stocks Close Slightly Higher After Cautious Session

European stocks closed higher on Tuesday, lifted by easing trade tensions, fairly buoyant German investor sentiment report and data showing a less than expected increase in U.S. consumer prices in the month of April.
RTTNews | 4小時44分鐘前
U.S. Consumer Prices Rise 0.2% In April, Slightly Less Than Expected

U.S. Consumer Prices Rise 0.2% In April, Slightly Less Than Expected

Consumer prices in the U.S. rose by slightly less than expected in the month of April, according to a report released by the Labor Department on Tuesday. The Labor Department said its consumer price index inched up by 0.2 percent in April after edging down by 0.1 percent in March. Economists had expected consumer prices to rise by 0.3 percent.
RTTNews | 8小時17分鐘前
Bayer Q1 Results Down, Sees Pharma Results At Top End Of View; Stock Gains

Bayer Q1 Results Down, Sees Pharma Results At Top End Of View; Stock Gains

Bayer AG on Tuesday confirmed its currency-adjusted 2025 targets after reporting lower earnings in its first quarter with slightly lower sales. The quarterly results reflected weak results in the Crop Science Division, despite growth in Pharmaceuticals and Consumer Health segments. Shares of the Pharmaceutical and life sciences major were gaining around 6 percent on the XETRA in Germany.
RTTNews | 9小時11分鐘前